As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

A new study has considered some of the potential benefits and risks of glucagon-like peptide 1 receptor agonists (GLP-1RAs), ...

Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed.

People who take weight-loss drugs based on GLP-1 receptor agonists seem to have reduced risk for a litany of diseases, ...

A new peer-reviewed study based on data from nearly 2M individuals highlights a wide range of clinical benefits and risks, ...

The use of weight-loss jabs may be associated with wider health benefits including lower risk of stroke and dementia, a study ...

"MicroAire closes deal to acquire adipose tissue biotech NEOSYAD" was originally created and published by Medical Device ...

Adults with obesity receiving once-weekly semaglutide 7.2 mg lost a higher proportion of their body weight at 72 weeks than ...

Compared to Lilly’s Zepbound (tirzepatide), the once-daily experimental drug would be simpler to produce.

Carbonated drinks known as sparkling, fizzy, seltzer and soda waters are thought to impact the waistline. A new study weighs in, but don’t expect too much.

Authorities work to eradicate the tomato brown rugose fruit virus, which has already had devastating impacts on South Australian growers. Luke Plapp is primed to target overall honours at the Tour ...